The Zacks Analyst Blog Highlights: Google, Sandisk, Syntel, Scientific Games and Alnylam Pharmaceuticals

 The Zacks Analyst Blog Highlights: Google, Sandisk, Syntel, Scientific Games
                         and Alnylam Pharmaceuticals

PR Newswire

CHICAGO, July 18, 2013

CHICAGO, July 18, 2013 /PRNewswire/ announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Google Inc. (Nasdaq:GOOG-Free
Report), Sandisk Corp. (Nasdaq:SNDK-Free Report), Syntel Inc.
(Nasdaq:SYNT-Free Report), Scientific Games Corp. (Nasdaq:SGMS-Free Report)
and Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY-Free Report).


Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of
the Day pick for free.

Here are highlights from Wednesday's Analyst Blog:

Will Google Beat Earnings Estimates?

Google Inc. (Nasdaq:GOOG-Free Report) is set to report second quarter 2013
results on Jul 18. Last quarter, it posted a 13.25% positive surprise. Let's
see how things are shaping up for this announcement.

Growth Factors This Past Quarter

Google's gross revenue in the first quarter of 2013 was down sequentially but
up from the year-ago year quarter. Additionally, Google's strong position in
the mobile segment enabled it to generate strong mobile revenue growth. Google
reported a gross margin of 57.9%, which was up sequentially due to a favorable

The company's success in the tablet market, initiatives in the e-commerce
segment (both retail and payment platforms), its Google Fibre initiative and
its Nexus and Chromebook platforms are quite encouraging. We believe Google's
growth strategies and solid execution will help the company to continue on the
growth path.

Earnings Whispers

Our proven model does not conclusively show that Google will beat earnings
this quarter. That is because a stock needs to have both a positive earnings
expected surprise prediction or ESP (Read: Zacks Earnings ESP: A Better
Method) and a Zacks Rank #1, #2 or #3 for this to happen. That is not the case
here as you will see below.

Negative Zacks ESP: The Most Accurate estimate stands at $8.89 per share while
the Zacks Consensus Estimate is higher at $9.04. That is a difference of

Zacks Rank #3 (Hold): Google's Zacks Rank #3 (Hold) when combined with a
negative ESP makes surprise prediction difficult.

We caution against stocks with Zacks Ranks #4 and #5 (Sell rated stocks) going
into the earnings announcement, especially when the company is seeing negative
estimate revisions momentum.

Other Stocks to Consider
Here are some other companies you may want to consider as our model shows that
they have the right combination of elements to post an earnings beat this

  oSandisk Corp. (Nasdaq:SNDK-Free Report), with an ESP of +4.55% and a Zacks
    Rank #1 (Strong Buy)
  oSyntel Inc. (Nasdaq:SYNT-Free Report), with an ESP of +3.81% and a Zacks
    Rank #1 (Strong Buy)
  oScientific Games Corp. (Nasdaq:SGMS-Free Report), with an ESP of +100.0%
    and a Zacks Rank #3 (Hold)

Alnylam: A Buying Opportunity

The stock price at Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY-Free Report)
surged significantly last week following positive top-line data on its
pipeline candidate ALN-TTRsc.

ALN-TTRsc is a ribo nucleic acid interference (RNAi) therapeutic targeting the
transthyretin gene that is being developed for the treatment of TTR-mediated
amyloidosis. The therapeutic is administered subcutaneously.

Results from the study revealed that ALN-TTRsc was successful in reducing
serum TTR protein levels to more than 80% in healthy volunteers, who were
enrolled in the study. The recent study results were at par with the
previously reported ALN-TTRsc results in non-human primates.

Data from the study also revealed that ALN-TTRsc was generally safe and well
tolerated. The randomized, double-blind, placebo-controlled, single- and
multi-dose, dose-escalation study is still ongoing. Alnylam will assess the
safety and tolerability of the candidate (single or multiple ascending
subcutaneous doses) along with other parameters like assessment of clinical
activity of the candidate as measured by serum TTR levels.

Alnylam plans to initiate a phase II study on ALN-TTRsc later this year
depending on the successful completion of the phase I study. Positive results
from the phase II study will lead to the initiation of a phase III study on
the candidate in 2014.

ALN-TTR02 is another promising candidate in Alnylam's pipeline. Last month,
Alnylam announced positive interim results from a phase II study on ALN-TTR02.
ALN-TTR02 is another RNAi therapeutic targeting the transthyretin gene for
treating TTR-mediated amyloidosis.

We are encouraged by the pipeline progress at Alnylam. We are positive on the
biopharmaceutical company despite the Zacks Rank #3 (Hold) carried by it. We
believe that the 8% dip in Alynam's price on the Nasdaq has made it more
affordable for investors after the lofty prices it touched last week.
Consequently, we view the current price as an attractive entry point for
long-term investors.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of
the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Register for your free subscription to Profit from the

Get the full Report on GOOG - FREE
Get the full Report on SNDK - FREE
Get the full Report on SYNT - FREE
Get the full Report on SGMS - FREE
Get the full Report on ALNY - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities
(including a broker-dealer and an investment adviser), which may engage in
transactions involving the foregoing securities for the clients of such

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers
displayed in this press release.

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.